A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
Public ClinicalTrials.gov record NCT02173301. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study objectives are the following: 1. To evaluate the efficacy of 3 doses of XP23829 compared to placebo for the treatment of moderate-to-severe chronic plaque-type psoriasis. 2. To evaluate the safety and tolerability of XP23829 in subjects with psoriasis. 3. To evaluate the pharmacodynamics (PD) of XP23829 through immunological analysis of peripheral blood samples.
Study identification
- NCT ID
- NCT02173301
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Interventions
- XP23829 400 mg QD Drug
- XP 23829 800 mg QD Drug
- XP23829 400 mg BID Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2014 (Type not available)
- Primary completion
- May 2015 (Actual)
- Completion
- Aug 2015 (Actual)
- Last update posted
- Apr 12, 2022
2014 – 2015
United States locations
- U.S. sites
- 31
- U.S. states
- 19
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| XenoPort Investigational Site | Birmingham | Alabama | 35233 | — |
| XenoPort Investigational Site | Phoenix | Arizona | 85032 | — |
| XenoPort Investigational Site | Hot Springs | Arkansas | 71913 | — |
| XenoPort Investigational Site | Encinitas | California | 92024 | — |
| XenoPort Investigational Site | Fremont | California | 94538 | — |
| XenoPort Investigational Site | Fullerton | California | 92663 | — |
| XenoPort Investigational Site | Denver | Colorado | 80210 | — |
| XenoPort Investigational Site | Snellville | Georgia | 30078 | — |
| XenoPort Investigational Site | Buffalo Grove | Illinois | 60089 | — |
| XenoPort Investigational Site | Carmel | Indiana | 46032 | — |
| XenoPort Investigational Site | South Bend | Indiana | 46617 | — |
| XenoPort Investigational Site | Overland Park | Kansas | 66215 | — |
| XenoPort Investigational Site | Louisville | Kentucky | 40217 | — |
| XenoPort Investigational Site | Owensboro | Kentucky | 42303 | — |
| XenoPort Investigational Site | Boston | Massachusetts | 02111 | — |
| XenoPort Investigational Site | Watertown | Massachusetts | 02472 | — |
| XenoPort Investigational Site | Troy | Michigan | 48084 | — |
| XenoPort Investigational Site | Warren | Michigan | 48088 | — |
| XenoPort Investigational Site | Omaha | Nebraska | 68114 | — |
| XenoPort Investigational Site | East Windsor | New Jersey | 08520 | — |
| XenoPort Investigational Site | Verona | New Jersey | 07044 | — |
| XenoPort Investigational Site | Rochester | New York | 14623 | — |
| XenoPort Investigational Site | Stony Brook | New York | 11790 | — |
| XenoPort Investigational Site | High Point | North Carolina | 27262 | — |
| XenoPort Investigational Site | Goodlettsville | Tennessee | 37072 | — |
| XenoPort Investigational Site | Dallas | Texas | 75230 | — |
| XenoPort Investigational Site | Dallas | Texas | 75231 | — |
| XenoPort Investigational Site | Dallas | Texas | 75246 | — |
| XenoPort Investigational Site | San Antonio | Texas | 78218 | — |
| XenoPort Investigational Site | San Antonio | Texas | 78229 | — |
| XenoPort Investigational Site | West Jordan | Utah | 84088 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02173301, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2022 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02173301 live on ClinicalTrials.gov.